Publications by authors named "Steven A Rubin"

20Publications

Evidence that a polyhexameric genome length is preferred, but not strictly required, for efficient mumps virus replication.

Virology 2016 06 6;493:173-88. Epub 2016 Apr 6.

Division of Viral Products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, MD, United States of America.

View Article and Find Full Text PDF
June 2016

Generation and propagation of recombinant mumps viruses exhibiting an additional U residue in the homopolymeric U tract of the F gene-end signal.

Virus Genes 2015 Aug 12;51(1):12-24. Epub 2015 May 12.

Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), OVRR, DVP, 10903 New Hampshire Avenue, Bldg 52/72, Silver Spring, MD, 20993, USA,

View Article and Find Full Text PDF
August 2015

Recent mumps outbreaks in vaccinated populations: no evidence of immune escape.

J Virol 2012 Jan 9;86(1):615-20. Epub 2011 Nov 9.

Division of Viral Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA.

View Article and Find Full Text PDF
January 2012

Gene-specific contributions to mumps virus neurovirulence and neuroattenuation.

J Virol 2011 Jul 4;85(14):7059-69. Epub 2011 May 4.

United States Food and Drug Administration, CBER, OVRR, DVP, 8800 Rockville Pike, Building 29A, HFM 460, Room 2C20, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
July 2011

A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines.

Biologicals 2010 Mar 6;38(2):278-83. Epub 2009 Nov 6.

FDA, Division of Viral Products, Lincoln Drive, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
March 2010

Presence of lysine at aa 335 of the hemagglutinin-neuraminidase protein of mumps virus vaccine strain Urabe AM9 is not a requirement for neurovirulence.

Vaccine 2009 Sep 4;27(42):5822-9. Epub 2009 Aug 4.

DVP/Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
September 2009

Identification of genetic mutations associated with attenuation and changes in tropism of Urabe mumps virus.

J Med Virol 2009 Jan;81(1):130-8

Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.

View Article and Find Full Text PDF
January 2009

Antibody induced by immunization with the Jeryl Lynn mumps vaccine strain effectively neutralizes a heterologous wild-type mumps virus associated with a large outbreak.

J Infect Dis 2008 Aug;198(4):508-15

Division of Viral Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Bethesda, Maryland 20892, USA.

View Article and Find Full Text PDF
August 2008

Functional consequences of attenuating mutations in the haemagglutinin neuraminidase, fusion and polymerase proteins of a wild-type mumps virus strain.

J Gen Virol 2007 Sep;88(Pt 9):2533-2541

DVP/Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
September 2007

Activation of microglia by borna disease virus infection: in vitro study.

J Virol 2006 Dec 4;80(24):12141-8. Epub 2006 Oct 4.

Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N. Wolfe Street, CMSC 8-121, Baltimore, MD 21287, USA.

View Article and Find Full Text PDF
December 2006

Changes in mumps virus neurovirulence phenotype associated with quasispecies heterogeneity.

Virology 2006 Jun 21;350(1):48-57. Epub 2006 Feb 21.

DVP/Office of Vaccines Research and Review, Center for Biologics, Evaluation and Research, Food and Drug Administration, Building 29A, Room 1A-21, 8800 Rockville Pike, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
June 2006

The rat-based neurovirulence safety test for the assessment of mumps virus neurovirulence in humans: an international collaborative study.

J Infect Dis 2005 Apr 22;191(7):1123-8. Epub 2005 Feb 22.

Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Adminstration, Bethesda, Maryland 20892, USA.

View Article and Find Full Text PDF
April 2005

Mouse neurotoxicity test for vaccinia-based smallpox vaccines.

Vaccine 2004 Mar;22(11-12):1486-93

Laboratory of Pediatric and Respiratory Viral Diseases, OD/Center for Biologics Evaluation and Research, Food and Drug Administration, HFM-460, Bldg. 29B, Room 5NN22, 8800 Rockville Pike, Bethesda, MD 20892, USA.

View Article and Find Full Text PDF
March 2004

Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype.

J Virol 2003 Nov;77(21):11616-24

DVP/Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20892, USA.

View Article and Find Full Text PDF
November 2003

Exploring the cerebellum with a new tool: neonatal Borna disease virus (BDV) infection of the rat's brain.

Cerebellum 2003 ;2(1):62-70

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

View Article and Find Full Text PDF
August 2003

Enhanced neurovirulence of borna disease virus variants associated with nucleotide changes in the glycoprotein and L polymerase genes.

J Virol 2002 Sep;76(17):8650-8

Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.

View Article and Find Full Text PDF
September 2002